SRZN: Surrozen Inc. Future Price to Earnings

SRZN (Surrozen Corp) - company brandmark

Surrozen, Inc. (SRZN) is managed by experts in regenerative medicine with a transparent approach to research. While Wnt pathway activation technology enables the restoration of liver and intestinal tissues, the lack of revenue and the risk of secondary offerings create uncertainty. This chart on GURU.Markets shows that the company's future P/E trajectory exhibits volatility, with the parameter stabilizing at 0.00.

Market Cap to Projected Earnings: Surrozen (SRZN) for 07/04/2022 - 11/15/2026

Analytical breakdowns for Surrozen, Inc.

- stock value and consensus price forecast:
Price Chart Surrozen Corp|SRZN - Price Target Chart
- market capitalization information:
Market Value Surrozen Inc.|SRZN - Total Company Value
- balance sheet equity data:
Net Assets per Single Share Surrozen|SRZN - Book Valuation of Business|Market Value to Book Value Ratio surrozen.com|SRZN - Company Total Asset Base
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Surrozen, Inc.|SRZN - Long-Term Debt to Capital|Short-Term Debt to Equity Surrozen|SRZN - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Surrozen|SRZN - Company Long-Term Loans and Borrowings|Company Short-Term Debt Surrozen|Quick Liquidity Indicator surrozen.com
- company profitability and valuation multiples indicators:
SRZN - Profit After Tax|Projected Future Earnings Surrozen, Inc.|SRZN - Market Cap to Earnings|Future Price to Earnings Surrozen|SRZN - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Surrozen|SRZN - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Surrozen|SRZN - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months surrozen.com|SRZN - Earnings per share growth this year|Earnings growth forecast for next year Surrozen, Inc.
- revenue and sales proceeds data:
SRZN - Company Sales|Company Future Sales Volume Surrozen Inc.|SRZN - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Surrozen, Inc.
Fundamental valuation:SRZN Surrozen Corp
Product sample of Surrozen, Inc.

The technological barrier of Surrozen, Inc. (SRZN), established through antibody patents and tissue regeneration research, drives the asset's investment attractiveness. By analyzing the company's forward P/E ratio history, an investor correlates current market capitalization with projected earnings for the following year, allowing for an assessment of overvaluation and the determination of a fair entry price based on expected profit growth.

Direct competitors

Future Price to Earnings Mesoblast Corp (MESO)|Future Price to Earnings LCTX (Lineage Corp)|Future Price to Earnings Cryo-Cell International Inc CCEL|FibroBiologics, Inc. - Future Price to Earnings|LGVN - Future Price to Earnings|Market Cap to Projected Earnings biorestorative.com BRTX|CELZ: Forward P/E Multiple